Sysmex (OTCMKTS:SSMXY) Issues FY 2026 Earnings Guidance

Sysmex (OTCMKTS:SSMXY) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 0.370-0.370 for the period, compared to the consensus EPS estimate of 0.440. The company issued revenue guidance of $3.4 billion-$3.4 billion, compared to the consensus revenue estimate of $3.1 billion.

Wall Street Analysts Forecast Growth

Separately, Citigroup lowered shares of Sysmex from a “strong-buy” rating to a “hold” rating in a report on Monday, March 16th. One research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold”.

Sysmex Stock Up 3.4%

SSMXY opened at $8.46 on Thursday. The firm has a 50 day moving average price of $8.75 and a 200 day moving average price of $9.42. The company has a market cap of $5.33 billion, a PE ratio of 17.63 and a beta of 1.10. Sysmex has a 1 year low of $8.15 and a 1 year high of $18.10. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.44 and a current ratio of 3.33.

Sysmex (OTCMKTS:SSMXY) last posted its earnings results on Thursday, February 12th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.01. The firm had revenue of $837.32 million during the quarter, compared to the consensus estimate of $819.99 million. Sysmex had a net margin of 8.86% and a return on equity of 9.27%. Sell-side analysts expect that Sysmex will post 0.44 earnings per share for the current year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.